Corcept Therapeutics Incorporated (CORT)
NEUTRALFundamental
58
Price
$123.83
Market Cap
$13.04B
Part 1 · What the company is worth
Overview
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$831M
Trailing 12 months (through 6/30/2026)
Net Income
$55M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$142M
Total Equity
$648M
Total Liabilities
$189M
Current Ratio
2.86
Interest Coverage
-
Debt/EBITDA
0.21
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$99.79
Current Price
$123.83
Margin of Safety
-24.1%
Fair Value Range
$64.86 - $134.71
Estimation Methods
Valuation Metrics
P/E Ratio
293.43
ROE
15.4%
P/B Ratio
18.88
P/FCF
124.60
Gross Margin
98.3%
ROIC
0.7%
Profitability Radar
Value Creation (Economic Moat)
ROIC
0.7%
WACC
8.0%
ROIC − WACC
-7.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (15)
- EPS shows upward trend
- Price CAGR 32.63%
- Gross Margin 98.3%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 8.4%
- Revenue Growth 5Y 16.6%
- Analyst Consensus 83% Buy
- Earnings Surprise avg 1684.0%
- Earnings Quality (OCF/NI) 1.99
Failed (9)
- ROIC 0.7%
- P/FCF 124.60
- P/B Ratio 18.88
- Operating Margin 0.8%
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 5.9%
- Net Margin Trend 6.6% vs 18.7%
- Piotroski F-Score 4/9
Unavailable (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 68 |
| Mr. Atabak Mokari | CFO & Treasurer | 48 |
| Mr. Sean Maduck | President of Endocrinology | 48 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 57 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 62 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 47 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 65 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | - |
| Ms. Monica Tellado | President of Emerging Markets | 52 |
| Mr. Roberto W. Vieira | President of Oncology | - |
Audit Risk
8
Board Risk
5
Compensation Risk
7
Shareholder Rights Risk
7
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for CORT, sourced from Markets Gazette.